Authors : S.I. Zaitzeva , S.L. Matveeva , T.G. Gerasimova , Y.N. Pashkov , D.A. Butov , V.S. Pylypchuk , V.M. Frolov and G.A. Kutsyna
Abstract: Safety and efficacy of phytoconcentrate Dzherelo (Immunoxel) as an adjunct immunotherapy for treatment of TB was compared to a standard anti-mycobacterial chemotherapy by enrolling 66 patients with active pulmonary tuberculosis. Among them 48 individuals presented with Multi-Drug Resistant (MDR) form of TB who were divided into 2 matching groups to receive either individualized Anti-TB Therapy (ATT) or ATT with 50 drops of Dzherelo twice-per-day. Patients were followed for 3 months and then assessed for sputum smear clearance rate, radiological findings and liver damage markers such as bilirubin, ALT, cholinesterase, gamma-glutamyl transpeptidase and thymol turbidity test. At the end of the 3rd month of follow-up 81.8% (27/33) of patients on Dzherelo had negative sputum smear, whereas, only 7 out 33 patients (21.2%) on ATT had converted (p = 0.0002). Administration of Dzherelo resulted in complete healing of pulmonary infiltrations and cavities in 12 (36.4%) patients in Dzherelo group, while only one patient (3%) treated with TB drugs had improved (p = 0.0008). Our results indicate that when Dzherelo is added to ATT it can produce significant clinical, microbiological and radiological improvements. Based on liver function tests Dzherelo was found to be safe and improved or reversed liver damage caused by ATT. Our findings support clinical studies by other investigators showing that immune intervention with Dzherelo accelerates and enhances the outcome of tuberculosis therapy.
S.I. Zaitzeva , S.L. Matveeva , T.G. Gerasimova , Y.N. Pashkov , D.A. Butov , V.S. Pylypchuk , V.M. Frolov and G.A. Kutsyna , 2009. Efficacy and Safety of Phytoconcentrate Dzherelo (Immunoxel) in Treatment of Patients with Multi-Drug Resistant TB (MDR-TB) in Comparison to Standard Chemotherapy. Research Journal of Medical Sciences, 3: 36-41.